Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax and Tocilizumab in Multiple Myeloma
NCT05391750Phase 1Active, not recruiting
- Sponsor
- Emory University
- Start
- Oct 2022
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of venetoclax in multiple myeloma (MM), sponsored by Emory University. Primary endpoint: Maximum tolerated dose at 21 days. Started Oct 2022; status: active, not recruiting.
02
Drugs
venetoclax
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05391750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05391750.